Literature DB >> 6135148

Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.

B T Mellion, L J Ignarro, C B Myers, E H Ohlstein, B A Ballot, A L Hyman, P J Kadowitz.   

Abstract

Recent studies have suggested that cyclic GMP accumulation in platelets mediates the antiaggregatory effects of certain nitrogen oxide-containing agents such as sodium nitroprusside, nitric oxide, nitrosoguanidines, and related agents. The vasodilator effect of these agents may involve the formation of S-nitrosothiol intermediates which relax vascular smooth muscle, elevate tissue levels of cyclic GMP, and activate guanylate cyclase. The purpose of this study was to investigate the effects of various synthetic S-nitrosothiols on human platelet aggregation. The S-nitroso derivatives of N-acetylpenicillamine, cysteine, and beta-D-thioglucose inhibited human platelet aggregation in a concentration-dependent fashion when ADP, collagen, U46619, or sodium arachidonate was employed as the aggregating agent. The antiaggregatory effects of the S-nitrosothiols were associated with a rapid and marked increase in intracellular platelet cyclic GMP levels, whereas cyclic AMP levels remained unchanged. Additionally, S-nitrosothiols disaggregated platelets which had been aggregated while concomitantly elevating platelet cyclic GMP levels. Moreover, guanylate cyclase, partially purified from the soluble fraction of human platelets, was markedly activated by S-nitrosothiols in a heme-dependent manner. Methemoglobin, a hemoprotein with a high affinity for nitric oxide, partially reversed the antiaggregatory effects, attenuated the accumulation of cyclic GMP, and inhibited the activation of guanylate cyclase by S-nitrosothiols. These data are consistent with the hypothesis that S-nitrosothiols could serve as active intermediates in the inhibitory action of sodium nitroprusside, nitric oxide, and related nitrogen oxides on platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135148

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

Review 1.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

2.  Low-dose L-arginine administration increases microperfusion of hindlimb muscle without affecting blood pressure in rats.

Authors:  Fumio Ohta; Tomo Takagi; Hiroyuki Sato; Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 3.  Role of nitric oxide in progression and regression of atherosclerosis.

Authors:  J P Cooke
Journal:  West J Med       Date:  1996-05

4.  Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.

Authors:  J J Killackey; B A Killackey; R B Philp
Journal:  Agents Actions       Date:  1985-12

5.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.

Authors:  Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka
Journal:  Ophthalmologica       Date:  2017-09-02       Impact factor: 3.250

6.  N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin.

Authors:  J Loscalzo
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

Review 7.  Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters.

Authors:  L J Ignarro
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

8.  Antiinflammatory properties of a hydroperoxide compound, structurally related to acetylsalicylic acid.

Authors:  J J Killackey; B A Killackey; I Cerskus; R B Philp
Journal:  Inflammation       Date:  1984-06       Impact factor: 4.092

9.  Polynitrosylated proteins: characterization, bioactivity, and functional consequences.

Authors:  D I Simon; M E Mullins; L Jia; B Gaston; D J Singel; J S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  S-nitroso-glutathione inhibits platelet activation in vitro and in vivo.

Authors:  M W Radomski; D D Rees; A Dutra; S Moncada
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.